DNA hypermethylation of CpG islands in the promoter region of genes is associated with transcriptional silencing. Treatment with hypo-methylating agents can lead to expression of these silenced genes. However, whether inhibition of DNA methylation in¯uences the expression of unmethylated genes has not been extensively studied. We analysed the methylation status of CDKN2A and CDKN2D in human lung cancer cell lines and demonstrated that the CDKN2A CpG island is methylated, whereas CDKN2D is unmethylated. Treatment of cells with 5-aza-2'-deoxycytidine (5-Aza-CdR), an inhibitor of DNA methyltransferase 1, induced a dose and duration dependent increased expression of both p16
Introduction
Methylation of cytosine residues in CpG sequences is a DNA modi®cation that plays a role in normal mammalian development (Costello and Plass, 2001; Li et al., 1992) , imprinting (Li et al., 1993) and X chromosome inactivation (Pfeifer et al., 1990) . To date, four mammalian DNA methyltransferases (DNMT) have been identi®ed (Bird and Wole, 1999) . Disruption of the balance in methylated DNA is a common alteration in cancer (Costello et al., 2000; Costello and Plass, 2001; Issa et al., 1993; Robertson et al., 1999) . A proposed reason for this disruption seen in cancer is that genes that are methylated in the promoter regions (such as critical tumor suppressor genes) may be transcriptionally silenced in the tumors, thus providing a growth advantage for these cells (Jones and Laird, 1999) . Usually, hypermethylation mediated gene silencing is limited to CpG islands in the promoter region of genes (Baylin et al., 1998; Chan et al., 2000) . In contrast, gene exons are more frequently hypermethylated at isolated CpGs (outside of CpG islands) and these methylated exons are not related to gene silencing (Herman and Baylin, 2000) . There are some reports that the degree of methylation of CpG islands outside of the promoter is positively correlated with an increase in gene expression (Chan et al., 2000; Glenn et al., 1996; Gonzalgo et al., 1998) .
Recently, evidence has been accumulating that methylation inhibits gene transcription either directly by interrupting the binding of transcription factors to promoters (Bird and Wole, 1999; Staiger et al., 1989) , or indirectly through methyl DNA binding proteins (MBPs) that bind preferentially to methylated DNA and recruit histone deacetylase enzymes (Nan et al., 1998; Ng and Bird, 1999) . The binding sites of some transcription factors such as AP-2, E2F, and c-myc contain CpG dinucleotides (Tate and Bird, 1993) . It has been postulated that methylation occurring at these binding sites may repress gene expression by blocking the access of transcription factors to the methylated DNA sequence (Kumari and Usdin, 2000; Staiger et al., 1989) . Alternatively, or in addition to this mechanism, MBPs have been shown to bind speci®cally to methylated DNA sequences and may compete with transcription factors for their binding sites . MBPs have also been demonstrated to recruit histone deacetylases to hypermethylated areas of the promoter, thereby increasing localized histone deacetylation (Bird and Wole, 1999; Nan et al., 1998) , resulting in gene repression.
However, some genes appear to be repressed by mechanisms distinct from methylation. For example, analysed the promoter region of the Wilms' tumor suppressor 1 gene (WT1) in 20 samples of normal breast epithelium and 19 primary breast carcinomas. They found that the promoter region was hypermethylated in six out of 19 tumors and in one out of 20 normal breast epithelial cells. However, WT1 mRNA or protein was expressed in the six tumors that were hypermethylated, whereas WT1 protein was not expressed in the 19 normal breast epithelial cells that were unmethylated ). In addition, Evron et al. (2001) have reported that although most breast tumors showed a correlation between hypermethylation of the cyclin D2 promoter and gene silencing, some did not. By analysing methylation in the promoter of cyclin D2 in 13 breast tumors by methylation speci®c PCR (MS-PCR), the investigators found that ®ve of 13 tumors were unmethylated in the promoter sequences. Among these samples, two showed cyclin D2 mRNA and protein expression whereas three did not. These observations suggest alternative transcriptional silencing pathways.
Loss of p16 INK4a and p15 INK4b protein expression in cancers has been frequently related to DNA methylation (Herman et al., 1995 (Herman et al., , 1996b Otterson et al., 1995) . The methylation status of the related INK4 family members, p18
INK4c and p19 INK4d has been less well studied. Among the four members of the INK4 family, methylation induced inactivation of p16
INK4a has been extensively reported in almost all human cancer cells (Herman et al., 1995) , whereas methylation mediated inactivation of p15
INK4b has been described principally in hematologic malignancies (Herman et al., 1996b) . As a member of the family of cyclin D kinase inhibitors, p19
INK4d is reported to play a similar function to p16
INK4a (Guan et al., 1996; Okuda et al., 1995) . This functional similarity to p16
INK4a implies that p19
INK4d may functionally replace p16 INK4a when there is deletion, mutation or methylation of CDKN2A.
Here we planned to investigate the methylation status of CDKN2D and determine if expression of p19
INK4d is in¯uenced by treatment of cells with a DNA demethylating agent (5-aza-2'-deoxycytidine (5-Aza-CdR)) or histone deacetylase inhibitor in human lung cancer cells. We also analysed methylation status of CDKN2A and expression of p16
INK4a in these cells. Our data show that the CpG islands of both genes have a distinct methylation status, but that there is a similar eect on protein expression after treatment with 5-Aza-CdR. In addition, low concentrations of 5-AzaCdR combined with a histone deacetylase inhibitor (depsipeptide) lead to a synergistic re-expression of both protein products. In contrast, higher concentrations of 5-Aza-CdR and depsipeptide induce decreased p16
INK4a expression but even higher p19 INK4d expression.
Results
The CpG island in the promoter of CDKN2D is unmethylated in human lung cancer cells Although evidence has shown that the promoter region of CDKN2A is hypermethylated in many human cancers and cancer derived cell lines (Herman et al., 1995; Otterson et al., 1995) , there has been no report studying the methylation status of CDKN2D. To investigate the CpG island in the promoter region of CDKN2D, we used the WebGene computer program (http://www.itba.mi.cnr.it/webgene/) to select CpG islands around the predicted promoter of CDKN2D. Brie¯y, as shown in Figure 1a , a non-repetitive region B (from 71100 to +1) was identi®ed as a CpG island. In this region the GC content is 67% and the observed/ expected presence of CpG is 0.84, consistent with this being a CpG island (Gardiner-Garden and Frommer, 1987) . In order to further narrow the putative promoter region of CDKN2D, three computer algorithms were used to predict the transcriptional start site. Using Promoter 2.0 (Knudsen, 1999) , McPromoter (Ohler et al., 2000) and Promoter Scan II (Prestridge, 1995) , the transcriptional start sites fall within a 350 bp region C that is between (7) 400 to (7)750 bp from the translational start site (+1). Our estimate regarding the promoter region of human CDKN2D is consistent with that suggested by another group (Yue Xiong, personal communication).
The methylation status of the CpG island in the region B (71000 to +1) was investigated with Southern blot hybridization using a methylation sensitive restriction enzyme NotI in 12 human lung cancer cell lines and normal human lung tissue. DNA from human normal lung tissue demonstrated bands of 24 and 5.8 kb following digestion with EcoRV or EcoRV/NotI, respectively (Figure 1b, lanes 1 and 2) . The 24 kb band after incubation with both enzymes would be consistent with lack of NotI digestion, suggesting methylation of the NotI site. DNA from all of the human lung cancer cell lines tested was completely digested with NotI (showing the 5.8 kb band), indicating an unmethylated NotI site in all human lung cancer cell lines tested ( Figure 1b) . As a comparison, we also performed Southern hybridization using SacII as a methylation-sensitive restriction enzyme to detect methylation status of CDKN2A in these human lung cancer lines as previously described (Herman et al., 1995; Otterson et al., 1995) (Figure 1c ). This analysis shows that H23, H211, H719 and H841 (lanes 4, 10, 12 and 14 respectively) exhibit a pattern consistent with methylation of the SacII site. H1155 (lane 6) exhibits a partial methylation pattern such that there are two bands of 4.3 kb and 3.4 kb seen after digestion with EcoRI/SacII. Other cell lines exhibit deleted (H290, H125 and H792) or unmethylated (H69, H82, H209 and N417) CDKN2A (Figure 1c) .
One drawback to Southern blot analysis to study methylation is that it detects methylation of one or at most two CpGs. To more thoroughly study the methylation status of the CpG island in CDKN2D, we designed three sets of ampli®cation primers in the putative promotor region ( Figure 1a , Region D) that includes 86 CGs from (7)774 to (+)18 from the translational start site to perform bisul®te sequencing. This region covers most of the CpG island and all three of the transcriptional start sites predicted by the computer algorithms noted above as well as part of exon 1. DNA from human normal lung tissue was utilized as a control. H23 and H719 cells with hypermethylated CDKN2A were selected for the bisul®te sequencing. Methylated CpGs are rare in this region in normal human lung tissue. When we examined ®ve separate clones from these cell lines and from normal human lung tissue, we found, on average, less than one methylated cytosine per clone out of 86 CGs in this region (data not shown). In Figure 1 Predicted promoter of CDKN2D and Southern blot analysis of the CDKN2A and CDKN2D CpG islands. (a) A repetitive region (region A, from 710 000 to 71100) and a nonrepetitive region (region B, from 71100 to +1) upstream of the open reading frame of CDKN2D were identi®ed by a computer program (WebGene). Region B (71100 to +1) was found to be a CpG island. An Alu repetitive element was immediately upstream of the CpG island. The predicted transcriptional start site was estimated to lie between position 7750 and 7400 bp (region C). Bisul®te DNA sequencing was performed in a region including 86 CGs and covering 792 bp (region D, from 7774 to +18 bp). The position of NotI and EcoRV sites is indicated. Figure not contrast, the CpG island in CDKN2A is heavily methylated. One study reported methylation of 31 ± 75% of cytosines from dierent clones of human bladder cancer cells were treated with bisul®te and then sequenced (Gonzalgo et al., 1998) . This data together with ours shows that methylation of the entire promoter is mirrored by the methylation status of the enzymes selected for Southern blot analysis (SacII for CDKN2A and Not1 for CDKN2D).
Inhibition of DNA methylation induces expression of silenced p16
INK4a and increases expression of p19
INK4d
Since H23 INK4d in untreated control samples. Treatment with 5-Aza-CdR at 1 mM for various times (from 6 to 72 h) also increased the expression of p19
INK4d in both cell lines (Figure 2a,b) . In addition, low concentrations of 5-Aza-CdR were sucient to induce an increase in p19
INK4d . The expression of p19
INK4d , for instance, was increased when cells were treated with 5-Aza-CdR at 0.1 mM (Figure 2c,d) . The 5-Aza-CdR induced increase in p19
INK4d reached a The 5-Aza-CdR induced p16 INK4a expression is due to a partial demethylation of CDKN2A (Figure 2e ). By MS-PCR, the completely methylated CDKN2A gene was partially changed to unmethylated status when both cell lines were treated with 5-Aza-CdR at 1 mM for 24 to 72 h (Figure 2e ). Since CDKN2D is unmethylated, we did not observe any changes in methylation status of this gene when cells were treated with 5-Aza-CdR by using MS-PCR (data not shown). INK4d . H719 cells were treated with 5-Aza-CdR (1 mM) for 24, 48 or 72 h, respectively, and then depsipeptide (0.05 mM) was added into the 5-Aza-CdR pretreated cells for the ®nal 6 h (18 ± 24, 42 ± 48 and 66 ± 72 h). Northern blot RNA analysis shows that 5-Aza-CdR (1 mM) induced a duration dependent increase in p19
INK4d mRNA and this increase was enhanced in the presence of depsipeptide (Figure 3a ). Since treatment with 5-Aza-CdR and depsipeptide induced a signi®cant enhancement of cell death (Zhu et al., 2001) , mRNA level was quanti®ed and normalized by a loading control, GAPDH (Figure 3b) . The relative mRNA level was then plotted as a ratio of the treated samples to untreated control (Figure 3c) . A 2.2 ± 2.4-fold increase in p19
INK4d mRNA was observed when H719 cells were treated with 5-Aza-CdR for 24 ± 72 h (Figure 3c ). Compared to 5-Aza-CdR treated cells, the p19
INK4d mRNA level was increased 3.2-fold (24 h), ®vefold (48 h) and 2.9-fold (72 h) in cells treated with 5-Aza-CdR and depsipeptide (Figure 3c) . However, when the same membrane was stripped and then hybridized with p16
INK4a probe, the increase in p16
INK4a mRNA level was not observed in the treatment with a combination of both drugs (data not shown).
These changes in p19 INK4d and p16 INK4a mRNA levels are also consistent with results from Western blot (Figure 4 ). Compared to 5-Aza-CdR (1 mM) treated H719 cells, a signi®cant increase in p19
INK4d was observed in the cells treated with 5-Aza-CdR (1 mM) together with depsipeptide (0.05 mM) (Figure 4a , top panel). In contrast to the expression of p19
INK4d , p16
INK4a expression was decreased after treatment with 5-Aza-CdR and depsipeptide in the same protein lysates (Figure 4a To investigate the in¯uence that 5-Aza-CdR and depsipeptide treatment induced apoptotic cell death may have on the expression of p16
INK4a and p19 INK4d , low concentrations of 5-Aza-CdR and depsipeptide were used in these same cells. As shown in Figure 4b , both p16
INK4a and p19 INK4d were increased in cells treated with lower concentrations of 5-Aza-CdR (0.25 mM) and depsipeptide (0.025 mM) compared to 5-Aza-CdR (0.25 mM) alone treated cells. Results from MTT assay further con®rmed that higher concentrations of 5-Aza-CdR and depsipeptide induce a signi®cant suppression of cell growth (Figure 4d ). Compared to 5-Aza-CdR alone treated cells, for example, cell growth rate decreases approximately ®vefold when H719 cells were treated with higher concentrations of the combination of 5-Aza-CdR and depsipeptide ( Figure 4d , lanes 2 ± 4 compared with lanes 5 ± 7). In contrast, a lower concentration of 5-Aza-CdR and depsipeptide compared with 5-Aza-CdR alone had only a marginal eect on cell growth rate such that the cell growth was only 35% less in the combination treated cells (Figure 4d , compare lanes 9 and 10).
Discussion
Our data regarding CDKN2A in this study provides direct evidence that methylation in CpG islands of CDKN2A is linked to gene silencing in human lung cancer cell lines as demonstrated by Southern blot, MS-PCR and Western blot (Figures 1 and 2) . Treatment with the DNA methyltransferase inhibitor (5-Aza-CdR) leads to re-expression of p16
INK4a , indicating that hypermethylation of CDKN2A is the primary inactivating event in these cells (Figure 2) . Interestingly, treatment with 5-Aza-CdR induced an increased expression of p19
INK4d (Figure 2 ). However, we found no consistent CpG methylation of CDKN2D by Southern blot (Figure 1b) , or bisul®te sequencing.
A lack of association between gene repression and promoter methylation status has been reported in several breast tumors and cancer cell lines by and . These investigators did not test whether treatment with DNA methyltransferase inhibitors (such as 5-Aza-CdR) could induce expression of unmethylated silenced genes. Recently, it was reported that inhibition of DNA methylation was able to induce expression of a silenced gene that was unmethylated in its promoter in melanoma cells (Soengas et al., 2001) . The Apaf-1 gene, which is involved in p53-dependent apoptosis (Soengas et al., 1999) , had no mutations or deletions in eight melanoma cell lines tested (Soengas et al., 2001) . By analysing the CpG island of Apaf-1 gene in the putative promoter region, no CpG methylation was found. However, a signi®cant increase in Apaf-1 expression was demonstrated after 5-Aza-CdR treatment, indicating that an alternative mechanism of epigenetic silencing for the inactivation of Apaf-1. The authors suggest the possibility of methylation related alterations of an enhancer element of Apaf-1 or of a methylated transcription factor being expressed leading to Apaf-1 expression.
Although the mechanism of enhanced p19
INK4d expression remains to be elucidated, DNA demethylation may reactivate an unknown gene or transcription factors that controls expression of CDKN2D. Alternatively, methylation of a gene enhancer or some other regulatory element outside of the promoter region might interfere with CDKN2D expression. The insulin-like growth factor 2 (IGF2) and H19 genes are imprinted, resulting in silencing of the maternal and paternal alleles, respectively, and share an enhancer (Yoo-Warren et al., 1988) . A region of paternalspeci®c methylation upstream of H19 contains an element that blocks enhancer activity (Elson and Bartolomei, 1997) . The activity of this element is regulated by an enhancer blocking protein CTCF and the binding of CTCF was abolished if its binding site is methylated (Bell and Felsenfeld, 2000; Hark et al., 2000) . These reports reveal that DNA methylation can modulate enhancer function to control gene expression. Another possibility for the increased expression of p19 INK4d by 5-Aza-CdR is that 5-Aza-CdR itself may activate CDKN2D by trapping the DNA methyltransferase enzyme in a covalent complex with DNA during replication (Juttermann et al., 1994) . In addition, as 5-Aza-CdR is incorporated into DNA, it is feasible that part of the eects we (and others) have observed may be related to an anti-metabolite mechanism of action through non-speci®c eects. We do not believe this to be the principal mechanism of action since the gene expression and synergistic cytotoxic eects we have noted are not seen when we utilize other cytosine analogs such as cytosine arabinoside in combination with HDAC inhibitors (unpublished observations). In addition, evidence from several groups indicates that repetitive DNA, such as Alu elements, may be a target for epigenetic silencing (Garrick et al., 1998; Tycko, 2000) . Usually, Alu elements are hypermethylated, which may induce loss of promoter occupancy or alter promoter con®gura-tion, thus leading to promoter inactivation (Gra et al., 1997) . We analysed an Alu repetitive region (Figure 1a , 71380 to 71164 bp from the translational start site) that is a boundary of the CpG islands of CDKN2D using Southern blot with a methylation sensitive enzyme, SmaI. We found very low level methylation in H23 cells and no methylation in H719 cells (data not shown). No methylation changes in the Alu element were found in H23 cells before or after 5-Aza-CdR treatment (data not shown). We therefore conclude that methylation status of the Alu repetitive is not relevant to 5-Aza-CdR induced increase in p19
INK4d expression. A synergistic eect of inhibition of histone deacetylase and DNA demethylation on gene expression has been reported previously (Cameron et al., 1999; Eden et al., 1998) . Consistent with these reports, our study shows that treatment with a low concentration of 5-Aza-CdR and depsipeptide enhanced the expression of p16
INK4a and p19 INK4d (Figure 4b ). Although the mechanism of this synergistic activity on gene expression is unclear, a model demonstrating a connection between histone acetylation and DNA methylation is attractive. A group of proteins with methyl DNA binding activity have been identi®ed and demonstrate a link between DNA methylation and histone acetylation (Hendrich and Bird, 2000) . One of these identi®ed methyl DNA binding proteins, MeCP2, is capable of binding to methylated CpG within DNA by a methyl-CpG-binding domain (Cross et al., 1994) and interacting with Sin3A by a transcriptional repression domain (Nan et al., 1998) . Since Sin3A interacts with histone deacetylases known to be associated with gene repression (Alland et al., 1997) , the methylated DNA is connected with gene repression by MeCP2. Furthermore, recent reports also demonstrated that DNA methyltransferase 1 is directly associated with histone deacetylases (Fuks et al., 2000; Rountree et al., 2000) .
However, in contrast to prior reports, when we treated cells with higher concentrations of 5-Aza-CdR and depsipeptide, the expression of p16 INK4a is decreased (Figure 4a ). This decrease in 16 INK4a expression may result from apoptotic cell death (Zhu et al., 2001) . Similarly, in this study, by analysing cell growth with the MTT assay, we also observed that growth suppression is signi®cantly higher with higher concentrations of 5-Aza-CdR and depsipeptide than at lower concentrations (Figure 4d ). Therefore, we conclude that the decrease in p16
INK4a expression after higher concentrations of 5-Aza-CdR and depsipeptide may be due to cell death. Supporting this, 5-Aza-CdR and depsipeptide-mediated cell death induced a decrease in p18
INK4c expression as well (Figure 4c ). Interestingly, however, p19
INK4d expression is still increased regardless of cell death induced by the higher concentrations of 5-Aza-CdR and depsipeptide treatment (Figure 4a ). The mechanism of p19 INK4d expression upon inhibition of DNA methylation and histone deacetylase is unclear. Future studies suggested by this work include an analysis of the methylation status of transcription factors predicted to bind in the CDKN2D promoter. An additional question for further investigation raised by this work is whether the increase in p19
INK4d expression plays a role in apoptotic cell death observed in cells treated with 5-Aza-CdR and depsipeptide.
Materials and methods

Cell culture and drug treatment
Human lung cancer cell lines H23, H69, H82, H125, H209, H211, H290, H719, H792, H841, H1155 and N417 were grown in RPMI medium 1640 with 10% fetal bovine serum and penicillin/streptomycin at 378C (5% CO 2 ). 5-Aza-CdR (Sigma, St. Louis, MO, USA) was dissolved in 50% acetic acid as a 10 mM stock solution. Aliquots were prepared and frozen at 7808C. Stock solutions of depsipeptide (kind gift of Michael Grever) were prepared in DMSO. Exponentially growing cells were treated with 5-Aza-CdR at dierent doses (from 0.1 to 10 mM) for 72 h, or treated with 5-Aza-CdR (1 mM) for dierent times (6 to 72 h). Fresh 5-Aza-CdR was replaced every 24 h and cells were harvested at 96 h after initial treatment. Depsipeptide (0.025 ± 0.05 mM) was added into 5-Aza-CdR pretreated cells for the ®nal 6 h of drug treatment at 18 ± 24, 42 ± 48 and 66 ± 72 h, respectively, to observe the changes of p16
INK4a and p19
INK4d expression.
Southern hybridization
Southern hybridization was performed as described previously (Otterson et al., 1995) . Brie¯y, DNA from normal human lung tissue or lung cancer cell lines was utilized. For CDKN2A, SacII was chosen as a methylation sensitive enzyme, whereas NotI was chosen as a methylation sensitive enzyme for CDKN2D. DNA was doubly digested with NotI/ EcoRV to detect methylation in CDKN2D and with SacII/ EcoRI to detect methylation in CDKN2A. The probes were prepared by PCR ampli®cation from human genomic DNA. The primers used were: CDKN2A, 5'-TTG GAA ACA AAG CCA TTT CC (forward) 5'-CCA AGA CGA AGG ACT TCA TTG (reverse); CDKN2D, 5'-CCG GAT GCA GAT TTT AGA GG (forward), 5'-CCC ATT GCA GCA CTT CAG TA (reverse). Appropriately sized PCR fragments were puri®ed from agarose gels, and subsequently labeled with a-32 P-CTP using the Prime it II kit (Stratagene, La Jolla, CA, USA).
MS-PCR
The methylation speci®c PCR (MS-PCR) was performed as described previously (Herman et al., 1996a) . Brie¯y, genomic DNA (1 mg) in a volume of 50 ml was denatured by NaOH (®nal concentration, 0.275 M) for 10 min at 378C. The denatured DNA was then treated with 10 ml of 10 mM hydroquinone, 520 ml of 3 M sodium bisul®te at 508C overnight. The bisul®te-modi®ed DNA was puri®ed with Qiaquick gel extraction kit (Qiagen, Germany) according to the manufacturer's instruction. The DNA was then precipitated with sodium acetate (®nal concentration, 0.45 M) and isopropanol. DNA was eluted with dH 2 O and used for PCR. The primers and PCR conditions are as follows: 
Northern blot analysis
Total RNA was extracted with TRIzol Reagent (Life Technologies, Gaithersburg, MD, USA). Messenger RNA was isolated from total RNA by an Oligotex mRNA Mini Kit (Qiagen, Valencia, CA, USA). CDKN2A exon 1a fragment (340 bp) was generated by PCR from normal human DNA. The exon 1a primers and PCR conditions are as follows: 5'-GAA GAA AGA GGA GGG GCT G (forward), 5'-GCG CTA CCT GAT TCA AAT TC (reverse), 958C for 10 min, 968C 30 s, 628C 40 s, 728C for 30 s, and 728C for 7 min, 35 cycles. The CDKN2D probe was generated from CDKN2D cDNA by RT ± PCR. The primers of CDKN2D and RT ± PCR conditions: 5'-CAA CCG CTT CGG CAA GAC (forward), 5'-CAG GGT GTC CAG GAA TCC A (reverse), 958C for 10 min, 968C for 39 s, 648C for 1 min, 728C for 66 s and 728C for 7 min, 35 cycles.
Northern blot analysis was performed as follows: 1 mg of mRNA was size-fractionated by agarose-formaldehyde gel electrophoresis (1%) and transferred to Nylon membrane (Hybond-N, Amersham, Amersham, UK). Hybridization with random-primed 32 P-labeled probes was performed at 428C overnight. Filters were washed (26SSC/0.1% SDS, 5 min twice at RT; 0.2 SSC/0.1% SDS, 5 min twice at RT and 15 min twice at 428C; 0.1 SSC/0.1% SDS, 15 min twice at 688C). The washed membrane was exposed to X-ray ®lm at 7808C for 4 ± 7 days and subsequently scanned with a phosphor imager.
Western immunoblotting
Cells were lysed in lysis buer (50 mM Tris-HCl, 250 mM NaCl, 5 mM EDTA, 50 mM NaF, 0.15% Igepal CA-630 and 1.5 mM PMSF). Equal amount of proteins (100 ± 150 mg) were size fractionated on 12.5 ± 15% SDS ± PAGE. Proteins were then transferred onto a nitrocellulose membrane. The membrane was blocked with blocking buer (5% nonfat milk, 200 mM NaCl, 50 mM Tris and 0.05% Tween-20). The blocked membrane was then incubated with primary antibodies at 48C overnight. After washing the membrane with TBS-T (20 mM Tris, 500 mM NaCl and 0.1% Tween-20) for 665 min, the membrane was incubated with secondary antibody at 48C for 1 h. The detection of speci®c protein binding was performed with a chemiluminescence kit (Amersham Pharmacia Biotech, Uppsala, Sweden). The antibodies and concentrations used are anti-p16
INK4a (PharMingen, San Diego, CA, USA, 1 mg/ml); anti-p18
INK4c (Ab-1) and anti-p19
INK4d (Ab-1) (Oncogene Research Products, Darmstadt, Germany, 2 mg/ml); a-tubulin (Oncogene Research Products, 0.3 mg/ml).
DNA bisulfite sequencing
DNA from human normal lung tissue (as control), H23 and H719 cell lines was bisul®te treated and puri®ed for PCR. The PCR products were gel extracted (Qiagen) and ligated into a plasmid vector, pCR2.1-TOPO using the TA cloning system (Invitrogen, Carlsbad, CA, USA). Plasmid-transformed bacteria TOP10F' was cultured overnight and the plasmid was isolated (Qiagen). According to the sequence of CpG islands around the putative CDKN2D promoter region (see Figure 1a) , three pairs of primers were designed for PCR. Pair A: 5'-TTA TTT GGT TGT TTG AAT GTG (forward), 5'-CCC ACA AAA CCT ACA TAA CC (reverse). Pair B: 5'-TTA TTG GTT ATG TAG GTT TTG TGG (forward), 5'-CCT AAC TCA CCC TCC CTC CT (reverse). Pair C: 5'-AGG AGGGAG GGT GAG TTA G (forward), 
